Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • XRX-225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Contact

Press Releases

News

News

  • Press Releases
  • Events
Apr 20, 2022 7:00am EDT

XORTX Receives Small and Medium Enterprise StatusĀ for the European Union

Apr 12, 2022 7:00am EDT

XORTX Receives No Objection Letter from Health Canada

Apr 07, 2022 7:00am EDT

XORTX Announces Grant of US Patent

Mar 31, 2022 7:00am EDT

XORTX Files IND with US FDA

Mar 23, 2022 7:00am EDT

XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

Mar 14, 2022 7:00am EDT

XORTX Therapeutics Announces Submission of Clinical Trial Application to Conduct Bridging Pharmacokinetics Study

Jan 31, 2022 7:00am EST

XORTX Provides Corporate Update

Jan 20, 2022 7:00am EST

XORTX Announces Appointment of Chief Technology Officer

Jan 10, 2022 7:00am EST

XORTX to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

Dec 21, 2021 6:00pm EST

XORTX Reports Annual & Special Meeting Results

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …12
  • arrow_forward
rss_feed News RSS
©2023 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap